7zwi: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==== | ==Pfs48/45 C-terminal domain bound to fab fragment of monoclonal antibody 32F3== | ||
<StructureSection load='7zwi' size='340' side='right'caption='[[7zwi]]' scene=''> | <StructureSection load='7zwi' size='340' side='right'caption='[[7zwi]], [[Resolution|resolution]] 1.90Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id= OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol= FirstGlance]. <br> | <table><tr><td colspan='2'>[[7zwi]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus] and [https://en.wikipedia.org/wiki/Plasmodium_falciparum Plasmodium falciparum]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7ZWI OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7ZWI FirstGlance]. <br> | ||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7zwi FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7zwi OCA], [https://pdbe.org/7zwi PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7zwi RCSB], [https://www.ebi.ac.uk/pdbsum/7zwi PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7zwi ProSAT]</span></td></tr> | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.9Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7zwi FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7zwi OCA], [https://pdbe.org/7zwi PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7zwi RCSB], [https://www.ebi.ac.uk/pdbsum/7zwi PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7zwi ProSAT]</span></td></tr> | |||
</table> | </table> | ||
== Function == | |||
[https://www.uniprot.org/uniprot/P4548_PLAF7 P4548_PLAF7] Gametocyte surface protein required for male fertility. | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
An effective malaria vaccine remains a global health priority and vaccine immunogens which prevent transmission of the parasite will have important roles in multi-component vaccines. One of the most promising candidates for inclusion in a transmission-blocking malaria vaccine is the gamete surface protein Pfs48/45, which is essential for development of the parasite in the mosquito midgut. Indeed, antibodies which bind Pfs48/45 can prevent transmission if ingested with the parasite as part of the mosquito bloodmeal. Here we present the structure of full-length Pfs48/45, showing its three domains to form a dynamic, planar, triangular arrangement. We reveal where transmission-blocking and non-blocking antibodies bind on Pfs48/45. Finally, we demonstrate that antibodies which bind across this molecule can be transmission-blocking. These studies will guide the development of future Pfs48/45-based vaccine immunogens. | |||
Structure of the malaria vaccine candidate Pfs48/45 and its recognition by transmission blocking antibodies.,Ko KT, Lennartz F, Mekhaiel D, Guloglu B, Marini A, Deuker DJ, Long CA, Jore MM, Miura K, Biswas S, Higgins MK Nat Commun. 2022 Sep 24;13(1):5603. doi: 10.1038/s41467-022-33379-6. PMID:36153317<ref>PMID:36153317</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 7zwi" style="background-color:#fffaf0;"></div> | |||
==See Also== | |||
*[[Monoclonal Antibodies 3D structures|Monoclonal Antibodies 3D structures]] | |||
== References == | |||
<references/> | |||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: | [[Category: Mus musculus]] | ||
[[Category: Plasmodium falciparum]] | |||
[[Category: Higgins MK]] | |||
[[Category: Ko KT]] | |||
[[Category: Lennartz FL]] | |||
Latest revision as of 16:35, 1 February 2024
Pfs48/45 C-terminal domain bound to fab fragment of monoclonal antibody 32F3Pfs48/45 C-terminal domain bound to fab fragment of monoclonal antibody 32F3
Structural highlights
FunctionP4548_PLAF7 Gametocyte surface protein required for male fertility. Publication Abstract from PubMedAn effective malaria vaccine remains a global health priority and vaccine immunogens which prevent transmission of the parasite will have important roles in multi-component vaccines. One of the most promising candidates for inclusion in a transmission-blocking malaria vaccine is the gamete surface protein Pfs48/45, which is essential for development of the parasite in the mosquito midgut. Indeed, antibodies which bind Pfs48/45 can prevent transmission if ingested with the parasite as part of the mosquito bloodmeal. Here we present the structure of full-length Pfs48/45, showing its three domains to form a dynamic, planar, triangular arrangement. We reveal where transmission-blocking and non-blocking antibodies bind on Pfs48/45. Finally, we demonstrate that antibodies which bind across this molecule can be transmission-blocking. These studies will guide the development of future Pfs48/45-based vaccine immunogens. Structure of the malaria vaccine candidate Pfs48/45 and its recognition by transmission blocking antibodies.,Ko KT, Lennartz F, Mekhaiel D, Guloglu B, Marini A, Deuker DJ, Long CA, Jore MM, Miura K, Biswas S, Higgins MK Nat Commun. 2022 Sep 24;13(1):5603. doi: 10.1038/s41467-022-33379-6. PMID:36153317[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||